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Little is known about the genetic factors that contribute to
familial colorectal cancer type X (FCCX), characterized by he-
reditary nonpolyposis colorectal carcinoma with no mismatch
repair defects. Genetic linkage analysis, exome sequencing,
tumor studies, and functional investigations of 4 generations
of a FCCX family led to the identiﬁcation of a truncating
germline mutation in RPS20, which encodes a component
(S20) of the small ribosomal subunit and is a new colon
cancer predisposition gene. The mutation was associated with
a defect in pre–ribosomal RNA maturation. Our ﬁndings show
that mutations in a gene encoding a ribosomal protein can
predispose individuals to microsatellite-stable colon cancer.
Evaluation of additional FCCX families for mutations in RPS20
and other ribosome-associated genes is warranted.Keywords: Colon Cancer; Hereditary Nonpolyposis Colorectal
Cancer; Ribosome; Exome Sequencing.
ereditary nonpolyposis colorectal cancer as deﬁned
1,2Abbreviations used in this paper: FCCX, hereditary nonpolyposis colo-
rectal cancer type X; rRNA, ribosomal RNA.
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entities with roughly comparable shares. Families with
germline mutations in DNA mismatch repair genes represent
Lynch syndrome (MIM 120435-6), with some 3000 unique
predisposing mutations known.3 Familial colorectal cancer
type X (FCCX) is a collective designation for families with no
evidence of DNA mismatch repair deﬁciency, wherein type X
refers to the as yet unknown nature of predisposition.4
We recently discovered germline mutations in the gene for
bone morphogenetic protein receptor type IA in 2 Amsterdam-
positive families of 18 FCCX families investigated (11%).5Among families with no bone morphogenetic protein receptor
type IA mutations, family F56 fulﬁlling the Amsterdam criteria
(Figure 1A) was chosen for closer scrutiny by genetic linkage
analysis, exomesequencing, and tumor investigations. Themean
age at colorectal cancer diagnosis was 52.3 years, with a 6–8
ratioofproximal todistal cancers.Genome-wide linkageanalysis
of the core pedigree resulted in the highest multipoint lod
score (1.6) for D8S507 (Genethon) and D8S1115 (Marshﬁeld),
both of which reside in the area of linkage between D8S255
and D8S1718 on chromosome 8p11-8q12 (Supplementary
Materials and Methods and Supplementary Figure 1).
However, because a few other chromosomal regions also
showed lod scores greater than 1, we opted for exome
sequencing and chose 4 siblings with colorectal cancer from
F56 to be included in the analysis (Figure 1B). A single
truncating alteration of RPS20 (c.147dupA, RefSeq
NM_001023.3) (Supplementary Figure 2A), a ribosomal
protein gene, turned out to be shared by all 4 affected
members investigated. It leads to frameshift and premature
truncation (p.Val50SerfsX23). RPS20 is located on 8q12.1 in
the region identiﬁed by genetic linkage analysis. The alter-
ation showed a full co-segregation with microsatellite-stable
colorectal cancer in F56 (Figure 1A), yielding a lod score of
3.0 for segregation. The sequence change was absent in
healthy controls (allele count 0 of 584); moreover, it has not
been reported in 4300 European Americans and 2203
African Americans (Exome Variant Server; available: http://
evs.gs.washington.edu/EVS/; date accessed: April 1, 2014).
Figure 1. (A) Pedigree of FCCX family 56. Numbers below the symbols are patient identiﬁers; key members also are marked with
a letter code A1–A8 for affected and U1 for unaffected. Carrier status for the c.147dupA in RPS20 is shown (þ, mutation carrier, -,
noncarrier). Arrow denotes the index person. Clinical diagnoses are speciﬁed in Supplementary Table 1. Nonessential pedigree
features were omitted or modiﬁed to protect conﬁdentiality. (B) Exomic sequencing of blood DNAs from individuals A2, A3, A5,
and A8 (see Supplementary Materials and Methods for details). The stepwise reduction in the number of insertions or deletions
and single-nucleotide variants (SNV) remaining for consideration is shown, ultimately resulting in 2 exonic alterations shared by
the 4 affected members. The RPS20 insertion or deletion (indel) alteration fulﬁlled the prerequisites of a predisposing mutation
and was characterized fully in this investigation whereas the available evidence (incomplete co-segregation, occurrence in
healthy controls, equivocal pathogenicity by predictions, as well as other data detailed in the Supplementary Materials and
Methods) suggested that the inhibitor of k light polypeptide gene enhancer in B cells, kinase b (IKBKB) SNV alteration was
unlikely to explain the colorectal cancer susceptibility of F56 and was excluded from further consideration. U, noncarrier.
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DNA from 25 other FCCX families from Finland and in tumor
DNA from 61 primary colorectal cancers and cancer cell
lines (Supplementary Materials and Methods); no RPS20
mutations were detected. Based on COSMIC (http://cancer.
sanger.ac.uk) and TCGA (http://cancergenome.nih.gov/)
databases (date accessed: May 28, 2014), at least 11 uniquemissense variants of RPS20 in cancer are known (mutation
frequency of up to 2.6% depending on tumor type), with
pathogenicity varying from benign to deleterious by in silico
predictions. At least one colon cancer case with a somatic
missense change (R79C) is included.6
Tumors from mutation carriers showed no loss of the
wild-type allele (Supplementary Figure 2B), arguing against
Figure 2. (A) Northern blot
analysis of total RNAs
from HeLa cells treated for
48 hours with a scramble
small interfering RNA
(siRNA) or a small inter-
fering RNA targeting
RPS20 messenger RNA,
and lymphoblastoid RNAs
from controls (C1–C3), a
noncarrier (U), and af-
fected mutation carriers
(A1–A4). Precursor rRNAs
were detected with a 5’
internal-transcribed spacer
1 probe.9 (B) Mature
rRNAs detected with 18S
and 28S probes. (C)
Quantiﬁcation of pre-rRNA
species by phosphor-
imaging after normaliza-
tion to 28S rRNA. For each
species, the value of the
mean of the 3 control
samples arbitrarily was set
to 1.
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The absence of loss of heterozygosity complies with obser-
vations from zebraﬁsh showing that ribosomal protein genes
act as haploinsufﬁcient suppressors of tumorigenesis.8
RPS20 is required during the late steps of 18S ribosomal
RNA (rRNA) formation.9 Indeed, Northern blot analysis
showed that small interfering RNA depletion of RPS20 in HeLa
cells led to a signiﬁcant increase of 21S pre-rRNAs (which are
distributed in 2 close bands in this cell type), as well as an
accumulation of 18S-E pre-rRNAs (Figure 2A). This was
accompanied by a strong decrease of the 18S/28S ratio
(Figure 2B). Patients carrying the RPS20 c.147dupA mutation
(A1–A4) showed a marked increase of 21S pre-rRNAs
compared with healthy unrelated controls (C1–C3), while the
18S-E pre-rRNA level was in the same range in control,
noncarrier, and patient samples (Figure 2C). The 18S/28S ra-
tios were unchanged in patient cells compared with controls
and a noncarrier. Altogether, these results show a late pre-
rRNA processing defect in mutation carrier cells consistent
with RPS20 haploinsufﬁciency. Polysome analysis showed a
slight increase in the 60S peak relative to the 40S peak in
mutation carriers compared with a noncarrier and a healthy
unrelated control (Supplementary Figure 3). Collectively, RNA
results suggest that the RPS20 mutation disturbs ribosome
biogenesis by affecting the equilibrium between the different
pre-rRNA species and the formation of mature 18S rRNA.
All RPSs are essential in human cells, except RPS25.9 The
ribosomal protein gene family comprises 80 genes,8 at least11 of which are known to be mutated in Diamond–Blackfan
anemia, a dominantly inherited form of pure red cell aplasia,
growth retardation, and congenital anomalies.10,11 No such
features were present in colon cancer patients from F56.
Why is the RPS20 mutation associated with colorectal can-
cer susceptibility, while mutations in 11 other ribosomal
protein genes cause predisposition to Diamond–Blackfan
anemia? Haploinsufﬁciency for RPS19 or RPS20 in mice was
shown to stabilize p53, which in turn had different effects in
different cell types.12 Mouse ﬁndings make it tempting to
speculate that cell type–speciﬁc effects of RPS20 hap-
loinsufﬁciency might play a role in RPS20-associated colon
tumorigenesis in human beings, with disturbed ribosome
biogenesis, altered p53 dosage, or various downstream
events as possible mediators. Among ribosomal proteins,
“detector” and “effector” types have been distinguished
based on contribution to p53 stress response.13 RPS20 was
proposed to be primarily of the detector type, with reduc-
tion perturbing ribosomal biogenesis9 (Figure 2 and
Supplementary Figure 3), leading to stabilization of p5313
(Supplementary Figure 4). Conversely, the constant activa-
tion of p53 consecutive to ribosomal stress induced by
RPS20 mutation could favor, in the long run, the selection of
cells that escape regulation by p53.
In summary, we show that inactivating germline muta-
tion of RPS20 is associated with a dominant predisposition
to colorectal cancer. This report links germline mutation of
RPS20 to human disease. Future investigations are
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FCCX families worldwide as well as the exact tumorigenic
mechanisms and the basis of apparent tumor-type speci-
ﬁcity. Finally, our study encourages investigations into the
possible involvement of other ribosomal protein genes in
colon cancer susceptibility.
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Supplementary Materials and Methods
Patients and Samples
This study was based on 26 FCCX families from Finland,
15 of which fulﬁlled the Amsterdam criteria1,2 and 11 ful-
ﬁlled the Bethesda criteria.3 The families had no DNA
mismatch repair defects in tumor tissue or in the germline4;
furthermore, germline mutations in bone morphogenetic
protein receptor type IA were excluded.5 In addition, 11
colorectal cancer cell lines including 7 with microsatellite
instability (HCA7, HCT115, HCT116, KM12, LIM1215, LoVo,
and RKO) and 4 microsatellite-stable (T84, SW480, SW837,
and CACO2), 50 primary colorectal cancers6 (18 with mi-
crosatellite instability and 32 microsatellite stable), as well
as 197 healthy blood donors from Finland and 95 from the
United Kingdom were screened for RPS20 mutations. The
Institutional Review Board of the Helsinki University Cen-
tral Hospital (Helsinki, Finland) approved this study.
Genome-Wide Linkage Analysis
Genetic linkage analysis of the core pedigree of F56 was
conducted at Ohio State University, taking advantage of
microsatellite markers from the Genethon collection (ABI
PRISM Linkage Mapping Set Version 2, Grand Island, NY)7
and at the University of Toronto using single-nucleotide
polymorphisms and microsatellite markers from the
Marshﬁeld collection (Human Mapping 10K array V2;
Affymetrix, Santa Clara, CA) (Supplementary Figure 1).
Parametric multipoint analysis was performed with
MERLIN v1.0-alpha (Ann Arbor, MI),8 using the following
parameters: autosomal-dominant mode of inheritance, gene
frequency of 0.001, 4 age-dependent liability classes,9 and 4
age-dependent phenocopy rates (0.00, 0.01, 0.03, and 0.05
corresponding to liability classes 1–4, respectively). Family
members with a colorectal polyp as the only tumor were
treated in 2 alternative ways, considering them either to
have an unknown status or to be affected.
Exome Sequencing and Data Analysis
Exome sequencing was conducted at the Institute for
Molecular Medicine Finland (Helsinki, Finland). Exome
sequencing was performed on an Illumina HiSeq 2000
platform (San Diego, CA) with Roche NimbleGen SeqCap EZ
Exome Library 2.0 (Roche, Basel, Switzerland). The probes
cover a total size of 44.1 Mb, comprising the whole human
exome and more than 20,000 genes. A variant calling
pipeline10 version 2.0 for quality control, short read align-
ment, variant identiﬁcation, and annotation were used for
the primary analysis of sequence data. Paired-end reads
were aligned to the GRCh37/Hg19 human genome build. An
algorithm10 developed at the Institute for Molecular Medi-
cine Finland was used for single-nucleotide variant calling,
and Pindel11 was used for insertion or deletion calling. The
minimum acceptable read depth was 7, and the required
quality score was 20 for single-nucleotide variants and 50
for insertions or deletions. The coverage depth was 20.
After ﬁltering out low-quality variations as well as common
and homozygous variants, the individual Excel (Microsoft,
Redmond, WA) ﬁles were analyzed by Microsoft Access
software to detect variants shared by all 4 family members.
As an alternative to the scheme shown in Figure 1B with all
4 colorectal cancer patients expected to be carriers of the
same mutation, we also analyzed the data allowing for any
one of the individuals to be a possible noncarrier (pheno-
copy). The latter method showed no additional noteworthy
candidates to be considered as susceptibility genes.
Exclusion of Inhibitor of k Light Polypeptide Gene
Enhancer in B Cells Kinase b as a Likely
Susceptibility Gene for F56
The c.1933C>T (RefSeq NM_001556.2) alteration in in-
hibitor of k light polypeptide gene enhancer in B cells kinase
b that was shared by all 4 affected family members besides
the RPS20 mutation (Figure 1B) constitutes a missense
change in a gene encoding an inhibitor of the k light poly-
peptide gene enhancer in B cells. Inhibitor of k light poly-
peptide gene enhancer in B cells kinase b is located on 8p11.2
in an interval ﬂanking the linked region, close to marker
D8S255. The alteration results in an arginine to tryptophan
substitution (p.R645W) and is suggested to be damaging by
SIFT (Rockville, MD) and a polymorphism byMutationTaster
(Berlin, Germany). Segregation analysis in the entire family
56 showed that the variant was absent in 1 member affected
with a colorectal tumor (Figure 1A, IV:1) and present in the
remaining colorectal cancer patients; in addition, it was
present in 1 clinically unaffected member (Figure 1A, III:12)
and absent in the remaining individuals not affected with
colorectal cancer. The variant occurred in healthy controls
with an allele count of 0.2% (1 of 450). Finally, inhibitor of k
light polypeptide gene enhancer in B cells kinase b has an
established disease connection, with homozygous germline
inactivation underlying severe combined
immunodeﬁciency.12
Sanger Sequencing of RPS20
RPS20 was screened for point mutations by exon-
speciﬁc sequencing with intronic primers from Sjoblom
et al13 and for large rearrangements by long-range genomic
polymerase chain reaction with primers 5’-ATTTTTGGTCCG
CACGCTCCT-3’ (from the 5’ untranslated region) and 5’-
CACTCTAAGATACCCATATATTCCACC-3’ (from the 3’ un-
translated region). The c.147dupA mutation in exon 3
(Supplementary Figure 2A) was detected with primers from
ﬂanking introns (forward primer: 5’-CTCGTTAATGTTA
GTGTAGAAGGTG-3’, reverse primer: 5’-GAACCTGAATTT
AGTCAACATC-3’).
Analysis of Loss of Heterozygosity in Tumor
Tissue
Fluorescent fragment analysis was performed as
described,14 taking advantage of 7 microsatellite markers
used for haplotype and linkage analysis (from pter to qter:
D8S255, D8S1828, D8S507, D8S260, D8S543, D8S1805, and
D8S270). Microsatellite marker D8S507 (Supplementary
Figure 2B) was investigated with forward primer 5’-
CCCCTATTCCTTCTGCCTTT-3’, and reverse primer 5’-CAG-
CATTTTTCCTCAGAGCAG-3’. Loss of heterozygosity analysis
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with the germline mutation (RPS20 c.147dupA) as an
intragenic marker (Supplementary Figure 2B) used forward
primer 5’-GCAGAAGTGAAGGCCTTAA-3’ and reverse primer
5’-GAACCTGAATTTATGCAACATC-3’.
Analysis of the Effects of RPS20 Mutation on
Pre-rRNA Processing by Northern Blot
Total RNAs were extracted by the TRIzol (Grand Island,
NY) method (modiﬁed from Chomczynski15). Northern blot
analysis of pre-rRNA species with probes hybridizing to the
internal-transcribed spacer 1 or 2 was performed as
described.16 HeLa cells treated for 48 hours with a scramble
small interfering RNA or a small interfering RNA targeting
RPS20messenger RNA (5’-GGUGGCAAUUCACCGAAUUdTdT-3’)
(Eurogentec, Liege, Belgium) and lymphoblastoid cells of in-
dividuals with or without the RPS20 c.147dupA mutation were
included in the analysis. Precursor rRNAs were detected with a
5’ internal-transcribed spacer 1 probe, which is complemen-
tary to the junction of the 18S and the internal-transcribed
spacer 1. Mature rRNAs were shown with 18S and 28S
probes. Each pre-rRNA species was measured by phosphor-
imaging, quantiﬁed using MultiGauge (Tokyo, Japan) software,
and normalized to 28S rRNA. For each species, the value of the
mean of the 3 control samples arbitrarily was set to 1. RNA
analyses were performed 3 times and led to similar results.
Analysis of Ribosomes by Sucrose Density
Gradient Centrifugation
Polysome analysis was conducted by sucrose density
gradient centrifugation of cytoplasmic fractions of
cycloheximide-treated cells as described in detail previously.16
Western Blot Analysis of p53 Protein
Total proteins were extracted from lymphoblastoid
cells, separated by electrophoresis on Novex (Carlsbad, CA)
NuPAGE 4%–12% Bis-Tris Gels (1.0 mm), blotted on
nitrocellulose membranes, hybridized with the primary
and secondary antibodies, visualized with the Amersham
(Buckinghamshire, UK) ECL Prime Western Blotting
Detection reagents, and scanned with the CCE camera. P53
rabbit polyclonal antibody (9282; Cell Signaling Technol-
ogy, Danvers, MA) with 1:1000 dilution was used as the
primary antibody to detect p53 protein. The housekeeping
protein glyceraldehyde-3-phosphate dehydrogenase
served as a loading control and was detected with rabbit
polyclonal antibody (1:1000 dilution, FL-335; Santa Cruz
Biotechnology, Dallas, TX).
URL Addresses for Web Resources Used
The following online resources were used: Online Men-
delian Inheritance in Man (OMIM), available at: http://
www.ncbi.nlm.nih.gov/Omim; Entrez Gene, available at:
http://www.ncbi.nlm.nih.gov/gene; Single Nucleotide Poly-
morphism database, available at: http://www.ncbi.nlm.nih.
gov/SNP; 1000 Genomes database, available at: http://
www.1000genomes.org; Sorting Intolerant from Tolerant
(SIFT), available at: http://sift.bii.a-star.edu.sg/; Muta-
tionTaster, available at: http://www.mutationtaster.org/;
Catalogue of Somatic Mutations in Cancer (COSMIC), avail-
able at: http://cancer.sanger.ac.uk; The Cancer Genome
Atlas (TCGA), available at: http://cancergenome.nih.gov/;
GeneCards, available at: http://www.genecards.org; and
Exome Variant Server (EVS), available at: http://evs.gs.
washington.edu/EVS/.
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Supplementary Table 1.Clinical Diagnoses of Members From F56 Tested for RPS20 c. 147dupA
Individual ID Mutation carrier status Tumor diagnosis (age at diagnosis in years)
II:2 Carrier Carcinoma of sigmoid colon (75)
III:1 Carrier Carcinoma of ascending colon (24), carcinoma of transverse colon (60)
III:2 Obligatory carrier Carcinoma of transverse colon (52)
III:4 Carrier Carcinoma of ascending colon (64)
III:7 Noncarrier Carcinoma of breast (55)
III:8 Carrier Carcinoma of cecum (50), carcinoma of rectum (59)
III:10 Carrier Carcinoma of sigmoid colon (43), carcinoma of rectum (45)
III:12 Noncarrier –
III:15 Noncarrier –
III:17 Noncarrier Hyperplastic polyp of cecum (47), tubular adenoma of ascending colon (53)
III:18 Carrier Carcinoma of descending colon (54)
III:20 Noncarrier –
IV:1 Carrier Carcinoid tumor of rectum (33)
Supplementary Figure 1. Results from genetic linkage anal-
ysis for chromosome 8 in F56, based on multipoint analysis
with the program MERLIN v1.0-alpha (Supplementary
Materials and Methods). The area between positions 61.133
and 79.265 on the Haldane marker map (interpolated
from DeCode genetic map provided by Affymetrix) assuming
no interference yielded lod scores over 1 (note that linkage
analysis was based on a more concise pedigree compared
to that shown in Fig. 1A, reﬂecting sample availability of the
time).
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Supplementary Figure 2. Analysis of blood and tumor DNAs for the ﬁrst (A) and second “hits” (B). A. Sequencing of RPS20
exon 3 with primers from ﬂanking introns shows a duplication of A (c.147dupA) in blood DNA from affected individuals from
family 56 (A5 given as an example). The duplication is marked with an arrow and highlighted in bold in the mutant sequence. B.
Fluorescent fragment analysis of normal (N) and tumor (T) DNA from three affected family members (A1, A5, and A6) shows
retention of heterozygosity at the ﬂanking microsatellite marker locus D8S507 (located 2 Mb downstream of RPS20) in tumor
DNA (left panel). The 117-bp fragment corresponds to the linked allele shared by all three individuals, whereas the 119-bp and
121-bp fragments represent the wild type allele. A similar analysis with the germline mutation (RPS20 c.147dupA) as an
intragenic marker conﬁrms the absence of LOH (right panel). The 205-bp fragment is derived from the wild-type allele and the
206-bp fragment from the mutant allele with the 1-bp insertion.
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Supplementary Figure 3. Analysis on sucrose gradient of
cytoplasmic ribosomes isolated from control (C4), non-carrier
(U1) or patient (A2-A4) lymphoblastoid cells. The proﬁles
display well-separated 40S and 60S peaks, a high contribu-
tion of 80S peak, and polysomes. Arrowheads indicate a
slight increase of the 60S peak in patient samples. The
alteration is analogous to that seen in HeLa cells treated with
RPS20 siRNA although less remarkable, in part reﬂecting a
prominent 80S peak that may mask 60S changes in lym-
phoblastoid cells.
Supplementary Figure 4.Western blot analysis of p53 pro-
tein expression in lymphoblastoid cells of two mutation car-
riers (A3 and A4), a proven non-carrier (U1) and a healthy
unrelated control (C4). The housekeeping protein GAPDH
was used as a loading control. The immunoblot shows an
increased level of p53 in mutation carriers compared to in-
dividuals with no RPS20 mutation. The ﬁnding is analogous
to the observation of elevated p53 dosage in RPL26 mutation
carriers in DBA (ref. 10 in the main paper).
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